Combination therapy for the treatment of diabetes
The present invention provides methods of treating, reducing, preventing, or inhibiting symptoms of diabetes and/or lowering plasma levels of HbA1c by co-administration of therapeutic or subtherapeutic doses of telenzepine and sertraline to a subject in need thereof.
1. A method of treating a diabetic condition in a subject in need thereof comprising co-administering to the subject telenzepine and sertraline.
2. The method of claim 1 , wherein one or both of the telenzepine and sertraline are administered in a therapeutically effective amount.
3. The method of claim 1 , wherein one or both of the telenzepine and the sertraline are administered in a sub-therapeutic amount.
4. The method of claim 1 , wherein the telenzepine is administered at a dose in the range of about 0.1-6 mg/day.
5. The method of claim 1 , wherein the telenzepine is administered at a dose in the range of about 1-3 mg/day.
6. The method of claim 1 , wherein the sertraline is administered at a dose in the range of about 50-200 mg/day.
7. The method of claim 1 , wherein the sertraline is administered at a dose in the range of about 50-150 mg/day.
8. The method of claim 1 , wherein the telenzepine is systemically administered.
9. The method of claim 1 , wherein one or both of the telenzepine and the sertraline are administered in a sustained release formulation.
10. The method of claim 1 , wherein the telenzepine and the sertraline are administered concurrently.
11. The method of claim 1 , wherein the telenzepine and the sertraline are administered sequentially.
12. The method of claim 1 , further comprising administering to the subject one or more anti-diabetic agents.
13. The method of claim 1 , wherein the subject has type 2 diabetes.
14. The method of claim 1 , wherein the subject has metabolic syndrome.
15. The method of claim 1 , wherein the subject is not overweight or obese.
16. The method of claim 1 , wherein the subject is a human.
17. A method of lowering plasma level of HbA1c in a subject in need thereof comprising co-administering to the subject telenzepine and sertraline.
18. The method of claim 17 , wherein the HbA1c level is lowered below a threshold level.
19. The method of claim 17 , wherein the HbA1c level is lowered by at least about 5%.
20. The method of claim 17 , wherein one or both of the telenzepine and sertraline are administered in a therapeutically effective amount.
21. The method of claim 17 , wherein one or both of the telenzepine and the sertraline are administered in a sub-therapeutic amount.
22. The method of claim 17 , wherein the telenzepine is administered at a dose in the range of about 0.1-6 mg/day.
23. The method of claim 17 , wherein the telenzepine is administered at a dose in the range of about 1-3 mg/day.
24. The method of claim 17 , wherein the sertraline is administered at a dose in the range of about 50-200 mg/day.
25. The method of claim 17 , wherein the sertraline is administered at a dose in the range of about 50-150 mg/day.
26. The method of claim 17 , wherein the telenzepine is systemically administered.
27. The method of claim 17 , wherein one or both of the telenzepine and the sertraline are administered in a sustained release formulation.
28. The method of claim 17 , wherein the telenzepine and the sertraline are administered concurrently.
29. The method of claim 17 , wherein the telenzepine and the sertraline are administered sequentially.
30. The method of claim 17 , further comprising administering to the subject one or more anti-diabetic agents.
31. The method of claim 17 , wherein the subject has a diabetic condition.
32. The method of claim 31 , wherein the subject is pre-diabetic.
33. The method of claim 31 , wherein the subject has type 2 diabetes.
34. The method of claim 31 , wherein the subject has metabolic syndrome.
35. The method of claim 17 , wherein the subject is not overweight or obese.
36. The method of claim 17 , wherein the subject is a human.